A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

April 16, 2024

Study Completion Date

April 29, 2024

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

Vonoprazan

Administered orally

Trial Locations (13)

10467

Advantage Clinical Trials, The Bronx

30342

Children's Center for Digestive Health Care, LLC, Atlanta

32503

Avanza Medical Research Center, Pensacola

33024

Med Research Associates, Inc, Hollywood

33614

International Center for Research, Tampa

36604

Strada Patient Care Center, Mobile

45429

PriMED Clinical Research, Dayton

46202

Riley Hospital for Children at IU Health, Indianapolis

70072

Tandem Clinical Research GI, LLC, Marrero

72211

Preferred Research Partners, Inc., Little Rock

75033

Stryde Research - NxT Step Pediatrics, Frisco

79902

Maspons Pediatric Gastro, El Paso

97030

Cyn3rgy Research, Gresham

Sponsors
All Listed Sponsors
lead

Phathom Pharmaceuticals, Inc.

INDUSTRY